Table 4.

Eligible patient demographics and clinical characteristics GOG 172. Summarizes the similarity of clinicopathologic characteristics of the patients that received IP chemotherapy under IP arm of GOG 172 prior to 25 days from surgery and those that received it in or after 25 days from surgery.

	<25 N=86	≥ 25 N=114	Test statistics
Age (yrs)	49.3 59.9 66.4	49.4 55.2 64.6	P=0.3331
BMI (kg/m2)	22.8 25.6 29.1	21.0 24.0 28.3	P=0.0771
Race/Ethnicity			P=0.8832
White	91.9%	90.4%
Black	2.3%	3.5%
Performance status			P= -2
0	100% (86)	100%(114)
1	0% (0)	0% (0)
Grade (differentiation)			P=0.5572
Good	15.1% (13)	10.5%(12)
Moderate	31.4% (27)	37.7%(43)
Poor	51.2% (44)	50.9%(58)
Histology			P=0.8222
Serous adenocarcinoma	76.7% (66)	77.2%(88)
Endometriod	9.3% (8)	7.9% (9)
Mixed	4.7% (4)	7.9% (9)
Clear-cell carcinoma	5.8% (5)	5.3% (6)
Gross residual disease			P=0.0272
No	30.2% (26)	45.6%(52)
Yes	69.8% (60)	54.4%(62)
No. completed IP cycles	1 3 6	1 5 6	P= 0.4811

a b c represent the lower quartile a, the median b, and the upper quartile c for continuous variables.

N is the number of non–missing values.

Numbers after percents are frequencies.

Tests used: 1Wilcoxon test; 2Pearson test